BioMedNewsBreaks – KBL Merger Corp. IV’s (NASDAQ: KBLM) Special Meeting to be Held November 5, 2020, 180 Life Sciences Featured in Exclusive Broadcast

October 23, 2020 11:09:36

KBL Merger Corp. (NASDAQ, KBLMKBL, KBLMR, KBLMW) (“KBL”), a special purpose acquisition company (“SPAC”) that previously announced the agreement to acquire 180 Life Sciences Corp., today announced postponement of the special meeting of its stockholders (the “Special Meeting”) to November 5, 2020. KBL determined to postpone the Special Meeting (originally scheduled for Monday, October 26, 2020) so that it better aligns with anticipated timing of the proposed business combination with 180 Life Sciences. As a result of this change, the Special Meeting will now be held at 10:00 a.m., local time, on November 5, 2020, at the offices of KBL located at 30 Park Place, Suite 64B, New York, NY 10007. Also as a result of this change, the date and time by which stockholders seeking to exercise redemption rights must tender their public shares physically or electronically and submit a request in writing that KBL redeem their public shares for cash to KBL’s transfer agent, Continental Stock Transfer & Trust Company, is being extended to 5:00 p.m. Eastern Time on November 3, 2020.

In addition, 180 Life Sciences today announced the availability of a broadcast titled “Banking on the Next Blockbuster Drug.” The broadcast covers the company’s placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ brands in the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. The piece discusses enormous amounts of time and money that pharmaceutical companies invest into the research and development of new drugs, and rare occasions when these are approved and generate more than $1 billion per year in sales, a benchmark in the industry commonly called a “blockbuster.” The piece discusses 180 Life Sciences team’s significant expertise in developing new therapeutics that were sold to big pharma for billions. Renowned for development of some of the largest-selling drugs to ever come to market, the team aims to “do it again with a pipeline of drug candidates in sequential stages of development that address large untapped markets. The founding scientists at 180 Life Sciences discovered the anti-TNF drug class that led to Remicade, the fourth all-time best-selling drug in the world.”

To view the full press release and listen to the podcast, visit and

About KBL Merger Corp. IV

KBL Merger Corp. is a blank check company that raised $115 million with the goal of identifying and acquiring a company with a strong value proposition mainly in the U.S. health care industry. KBL Merger Corp. focused on this industry due to its management’s deep experience in this large, growing segment of the U.S. economy. Marlene Krauss, MD is the CEO of KBL Merger Corp. This is Dr. Krauss’ fourth SPAC in the healthcare space. She has invested more than $1 billion through three institutional venture capital funds, numerous IPOs and three prior SPACS. For more information, visit

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork